Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound Sodium Alginate Oral Suspension in GERD
NCT02619747Phase 3Terminated
- Sponsor
- Reckitt
- Start
- Apr 2014
- Primary completion
- Mar 2017
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Sodium alginate in gastroesophageal reflux disease (GERD), sponsored by Reckitt. Started Apr 2014; status: terminated.
02
Drugs
Sodium alginate
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT02619747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02619747.